AECOM Technology (NYSE: ACM) reported earnings on Nov. 13. Here are the numbers you need to know.

The 10-second takeaway
 For the quarter ended Sep. 30 (Q4), AECOM Technology missed estimates on revenues and met expectations on earnings per share.

Compared to the prior-year quarter, revenue contracted slightly and GAAP earnings per share dropped to a loss.

Margins dropped across the board.

Revenue details
 AECOM Technology logged revenue of $2.08 billion. The seven analysts polled by S&P Capital IQ looked for a top line of $2.21 billion on the same basis. GAAP reported sales were 1.7% lower than the prior-year quarter's $2.12 billion.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
 EPS came in at $0.83. The eight earnings estimates compiled by S&P Capital IQ anticipated $0.83 per share. GAAP EPS were -$2.05 for Q4 against $0.74 per share for the prior-year quarter.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Margin details
 For the quarter, gross margin was 6.9%, 30 basis points worse than the prior-year quarter. Operating margin was 6.1%, 20 basis points worse than the prior-year quarter. Net margin was -10.8%, 1,490 basis points worse than the prior-year quarter.

Looking ahead
 Next quarter's average estimate for revenue is $2.04 billion. On the bottom line, the average EPS estimate is $0.30.

Next year's average estimate for revenue is $8.53 billion. The average EPS estimate is $2.43.

Investor sentiment
 The stock has a four-star rating (out of five) at Motley Fool CAPS, with 588 members out of 606 rating the stock outperform, and 18 members rating it underperform. Among 114 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 111 give AECOM Technology a green thumbs-up, and three give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on AECOM Technology is outperform, with an average price target of $24.18.